A 28-year-old woman from Delhi presents with a 3-year history of irregular periods occurring every 2–3 months, associated with progressive weight gain (BMI 31 kg/m²) and facial hirsutism. Menarche was at age 13 with regular cycles initially. On examination, she has acne, central obesity, and dark velvety skin over the neck and axillae. Pelvic ultrasound shows multiple small follicles (8–10 mm) arranged peripherally in both ovaries with increased stromal echogenicity. Fasting blood glucose is 102 mg/dL, and free testosterone is elevated at 8 pg/mL (normal <4 pg/mL). FSH:LH ratio is 1:3. Which of the following is the most appropriate first-line pharmacological intervention?

Explanation

## Diagnosis and Pathophysiology **Key Point:** This patient meets Rotterdam criteria for PCOD (polycystic ovarian disease): irregular cycles, clinical/biochemical hyperandrogenism (hirsutism, elevated free testosterone), and polycystic ovaries on ultrasound. The elevated LH:FSH ratio (3:1) and insulin resistance (fasting glucose 102 mg/dL, BMI 31) confirm the diagnosis. ## First-Line Management Strategy **High-Yield:** Metformin is the first-line pharmacological agent for PCOD with metabolic dysfunction (insulin resistance, impaired fasting glucose, or obesity). It improves: - Insulin sensitivity and reduces hyperinsulinemia - Ovulatory function and menstrual regularity - Androgen levels (secondary to reduced insulin-driven ovarian steroidogenesis) - Long-term cardiovascular and metabolic risk **Clinical Pearl:** The presence of impaired fasting glucose (102 mg/dL, fasting) in a young woman with PCOD is a red flag for metabolic syndrome and mandates early metformin initiation, even before antiandrogen therapy. ## Why Metformin First? | Intervention | Indication | Role in This Case | |---|---|---| | **Metformin** | Insulin resistance, metabolic dysfunction, fertility planning | **First-line** — addresses root pathophysiology | | Spironolactone | Hyperandrogenic symptoms (acne, hirsutism) | Second-line; add if hirsutism persists after metformin | | Leuprolide | GnRH agonist; rarely used in PCOD | Reserved for severe hyperandrogenism or endometriosis; not first-line | | Clomiphene | Ovulation induction | Only if fertility is the immediate goal; not for metabolic/menstrual management | **Mnemonic:** **METRO** — **M**etformin first, **E**thinyl estradiol (OCP) or **T**herapy for hirsutism, **R**eassess after 3–6 months, **O**vulation induction if needed. ## Expected Outcomes with Metformin - Menstrual regularity improves in 60–70% of patients within 3–6 months - Androgen levels decline as insulin resistance improves - Weight loss of 2–3 kg (modest but clinically meaningful) - Reduced progression to type 2 diabetes **Tip:** Lifestyle modification (diet, exercise, 5–10% weight loss) should accompany metformin. If hirsutism or acne persist after 3–6 months of metformin, add a combined oral contraceptive (COC) or spironolactone.